Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL  
50.14
-1.79 (-3.45%)
Earnings Announcements

Zentalis Pharmaceuticals Says Net Loss Was $50.4 Million For Three Months Ended March 31, 2021

Published: 05/17/2021 11:16 GMT
Zentalis Pharmaceuticals Inc (ZNTL) - Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update.
Zentalis Pharmaceuticals - Cash and Marketable Securities Position As of March 31, 2021 to Fund Operating Expenses and Capex Requirements Into 2023.
Zentalis Pharmaceuticals - Net Loss Was $50.4 Million for Three Months Ended March 31, 2021, Compared to $16.2 Million for Three Months Ended March 31, 2020.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.13

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.14

More details on our Analysts Page.